Lasa Supergenerics Limited

LASA

INE670X01014

Pharmaceuticals

End-of-day quote NSE India S.E. Other stock markets 03:30:00 04/06/2024 am IST			5-day change	1st Jan Change
20 ^INR	-4.99%		-11.70%	-33.11%

30/05	Lasa Supergenerics Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
26/04	Lasa Supergenerics CFO Steps Down	MT

Lasa Supergenerics Limited Announces Resignation of Ankita Shetty as Company Secretary and Compliance Officer

February 09, 2023 at 01:30 pm IST

Lasa Supergenerics Limited announced that Ms. Ankita Shetty, company secretary and compliance officer of the company have tendered her resignation, effective 9 February 2023.

Latest news about Lasa Supergenerics Limited

Lasa Supergenerics Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	30/05	CI
Lasa Supergenerics CFO Steps Down	26/04	MT
Lasa Supergenerics Limited Announces Resignation of Ravi Shankar Kabra as Chief Financial Officer	26/04	CI
Lasa Supergenerics Limited Appoints Umesh Pawar as an Additional Director (Executive Director)	08/03	CI
Lasa Supergenerics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13/02	CI
Lasa Supergenerics Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	10/11	CI
Lasa Supergenerics Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/23/14	CI
Lasa Supergenerics Limited Announces Change in Corporate Office Address	27/23/27	CI
Lasa Supergenerics Limited Reports Earnings Results for the Full Year Ended March 31, 2023	09/23/09	CI
Lasa Supergenerics Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	09/23/09	CI
Lasa Supergenerics Limited Approves Appointment of Mitti Jain as Company Secretary & Compliance Officer	21/23/21	CI
Lasa Supergenerics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/23/14	CI
Lasa Supergenerics Limited Announces Resignation of Ankita Shetty as Company Secretary and Compliance Officer	09/23/09	CI

Chart Lasa Supergenerics Limited

Duration

Period

More charts

Lasa Supergenerics Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (API) bulk drugs products. The Company is engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, pharmaceuticals, drugs, and others. It is specialized in catalyst chemistry and manufactures anthelmintic/ veterinary API products with the production capabilities and product categories in India. The Company's products include API products, other API products, animal feed ingredients and reagents for therapeutic use. Its API products include Fenbendazole, Toldimphos sodium, Cyromazine, Albendazole, Riclabendazole, Rafoxanide, Ornidazole, 2,6-Diiodo-4-Nitrophenol, Ricobendazole, Oxfendazole, Closantel Base, Closantel sodium, Nitroxynil, Halquinol, and Oxyclozanide. The Company's manufacturing facility is located at Chiplun, Maharashtra.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Veterinary Drugs

	1st Jan change	Capi.
LASA SUPERGENERICS LIMITED	-33.11%	12.69M
ZOETIS INC.	-12.91%	78.65B
ELANCO ANIMAL HEALTH INCORPORATED	+22.15%	8.77B
BLUESTAR ADISSEO COMPANY	+25.50%	3.68B
VIRBAC	-2.50%	3.21B
VIMIAN GROUP AB	+12.67%	1.77B
JINYU BIO-TECHNOLOGY CO., LTD.	-25.16%	1.24B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-27.23%	1.2B
WUHAN KEQIAN BIOLOGY CO.,LTD	-18.50%	1.05B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.	-7.57%	951M